ArticleMolecular biotechnology2023
MiR-29c-3p/C1QTNF6 Restrains the Angiogenesis and Cell Proliferation, Migration and Invasion in Head and Neck Squamous Cell Carcinoma.
Article in Molecular biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.
- Prognostic Impact of miR-34a in Head and Neck Squamous Cell Carcinoma: A Systematic Review with Meta-Analysis and Trial Sequential Analysis.International journal of molecular sciences · 2026Pooled it
- Mechanotransduction unifies healthy nondiabetic wound healing over time by promoting a Cd14+/C1qa+ fibroblast subpopulation.The Journal of investigative dermatology · 2026Article
- MicroRNAs as Emerging Therapeutic Targets Modulating the Tumor Microenvironment in Head and Neck Squamous Cell Carcinoma.International journal of molecular sciences · 2025Review
- Review
- Comparative analysis of miRNA-mRNA interaction prediction tools based on experimental head and neck cancer data.Einstein (Sao Paulo, Brazil) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
In our research, we studied the regulatory effect of miR-29c-3p on HNSCC progression. First, bioinformatics approach was utilized to find significantly differentially expressed genes in The Cancer Genome Atlas-HNSCC. Then the target miRNA and its target mRNA were screened out. Next, qRT-PCR was utilized to examine miR-29c-3p expression in HNSCC and the adjacent tissue. Western blot was introduced to test the protein level of C1QTNF6. Besides, the results of MTT, wound healing, transwell and angiogenesis assays verified the proliferation, migration, invasion and angiogenesis of HNSCC cells. Finally, the targeted relationship of miR-29c-3p and C1QTNF6 was confirmed through dual-luciferase assay. Our study found the negative correlation of miR-29c-3p and C1QTNF6 in HNSCC. Besides, overexpressed miR-29c-3p suppressed proliferation, migration, invasion, and angiogenesis of HNSCC cells. Additionally, overexpressed C1QTNF6 facilitated these biological functions of HNSCC cells while upregulating miR-29c-3p reversed such effect. Altogether, miR-29c-3p was proven to suppress the tumor-promoting effects and angiogenesis in HNSCC by targeting C1QTNF6. We also revealed a novel mechanism of HNSCC progression. MiR-29c-3p/C1QTNF6 might be a target in HNSCC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.